Nyxoah Reports First Quarter 2023 Financial and Operating Results
Nyxoah Reports First Quarter 2023 Financial and Operating Results
Mont-Saint-Guibert, Belgium – May 16, 2023 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the first quarter of 2023.
Recent Financial and Operating Highlights
- Completed all 115 implants in the DREAM U.S. pivotal trial, with 12-month data expected in the first quarter of 2024.
- Initiated the modular PMA submission with the filing of the first module.
- Submitted 12-month data1 on the first 34 DREAM patients as a late-breaking abstract to SLEEP 2023 demonstrating a 65% AHI responder rate, a 76% ODI responder rate and safety in-line with expectations. The abstract will be presented in a late-breaking poster session on June 6th. These data are preliminary and not conclusive of final DREAM success.
- Implanted the first patients in the ACCCESS U.S. IDE pivotal study to treat complete concentric collapse (CCC). Implant completion expected in 2024.
- Hired Christoph Eigenmann as Chief Commercial Officer.
- Raised €19 million from new and historical shareholders including ResMed, Cochlear and Robert Taub, Nyxoah’s Chairman and Founder.
- Ended the quarter with 40 active German accounts and quarterly sales of €441 thousand.
- Expanded European market access with first implants in Austria.
- Strengthened the supply chain with the Belgium manufacturing facility receiving clearance from the EU notified body.
“In 2023, our focus is in the U.S. on DREAM patient follow up resulting in reaching the primary endpoints. I am excited by the data on the first 34 patients and look forward to sharing the full abstract results at SLEEP 2023 next month. Our increasing conviction in DREAM outcomes is accelerating investment in our commercial organization, starting with the addition of Christoph as Chief Commercial Officer,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer. “Christoph’s hire, along with the €19 million raised from key investors, puts us in a strong position as we embark on our next stage of growth.”
First Quarter 2023 Results
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL INFORMATION – CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS FOR THE THREE MONTHS ENDED MARCH 31, 2023 (in thousands)
|For the three months ended March 31|
|Cost of goods sold||(175)||(289)|
|Research and Development Expense||(6,157)||(3,595)|
|Selling, General and Administrative Expense||(5,551)||(4,193)|
|Operating loss for the period||€(11,396)||€(7,281)|
|Loss for the period before taxes||€(11,729)||€(6,493)|
|Loss for the period||€(11,911)||€(6,701)|
|Loss attributable to equity holders||€(11,911)||€(6,701)|
|Other comprehensive loss|
|Items that may be subsequently reclassified to profit or|
loss (net of tax)
|Currency translation differences||(28)||( 102)|
|Total comprehensive loss for the year, net of tax||€(11,939)||€(6,803)|
|Loss attributable to equity holders||€(11,939)||€(6,803)|
|Basic Loss Per Share (in EUR)||€(0.460)||€(0.260)|
|Diluted Loss Per Share (in EUR)||€(0.460)||€(0.260)|
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL INFORMATION – CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS OF MARCH 31, 2023 (in thousands)
|December 31 2022|
|Property, plant and equipment||€2,721||€2,460|
|Right of use assets||3,669||3,159|
|Deferred tax asset||50||47|
|Other long-term receivables||169||173|
|Other current assets||1,663||1,284|
|Cash and cash equivalents||33,664||17,888|
|EQUITY AND LIABILITIES|
|Capital and reserves|
|Share based payment reserve||6,582||5,645|
|Other comprehensive income||148||176|
|Total equity attributable to shareholders||€125,026||€120,324|
|Deferred tax liability||−||−|
|Current tax liability||3,619||3,654|
|Total equity and liabilities||€150,953||€146,071|
Revenue was €441,000 for the first quarter ending March 31, 2023, compared to €660,000 for first quarter ending March 31, 2022.
Cost of Goods Sold
Cost of goods sold was €175,000 for the three months ending March 31, 2023, representing a gross profit of €266,000, or gross margin of 60.3%. This compares to total cost of goods sold of €289,000 in the first quarter ending March 31, 2022, for a gross profit of €371,000, or gross margin of 56.2%.
Research and Development Expenses
Research and development expenses were €6.2 million for the three months ending March 31, 2023, versus €3.6 million for the prior year period, driven by an acceleration in clinical activities, notable the start of the ACCCESS study.
Selling, General and Administrative Expenses
Selling, general and administrative expenses rose to €5.6 million for the first quarter of 2023, up from €4.2 million in the first quarter of 2022. This was due primarily to increased commercial efforts in Germany and other European markets, as well as investments in Nyxoah’s corporate infrastructure. The Company expects to continue adding headcount across the organization ahead of the U.S. commercial launch.
Total operating loss for the first quarter 2023 was €11.4 million versus €7.3 million in the first quarter of 2022. This was driven by the acceleration in the Company’s R&D spending, as well as ongoing commercial and clinical activities.
As of March 31, 2023, cash and financial assets totaled €96.1 million, compared to €94.9 million on December 31, 2022. Total cash burn was approximately €4.9 million per month during the first quarter of 2023.
First Quarter 2023 Report
Nyxoah’s financial report for the first quarter of 2023, including details of the consolidated results, are available on the investor page of Nyxoah’s website (https://investors.nyxoah.com/financials).
Conference call and webcast presentation
Nyxoah will conduct a conference call open to the public today at 10:30pm CET / 4:30pm ET, which will also be webcast. To participate in the conference call, please access the following link to register for a dial-in number: https://edge.media-server.com/mmc/p/imeku8f7
A question-and-answer session will follow the presentation of the results. To access the live webcast, go to https://investors.nyxoah.com/events. The archived webcast will be available for replay shortly after the close of the call.
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission (“SEC”) on March 24, 2022, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
David DeMartino, Chief Strategy Officer
+1 310 310 1313
1 For the trial to be successful, of the 115 patients, at least 63% of patients need to be AHI and ODI responders at the 12-month follow-up.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Kallelse till årsstämma i Anoto Group AB (publ)1.6.2023 08:00:00 CEST | Pressemelding
Aktieägarna i Anoto Group AB (publ) (“Bolaget”), kallas härmed till årsstämma att äga rum fredagen den 30juni 2023kl. 10.00 i Setterwalls Advokatbyrås lokaler med adress Sturegatan 10 i Stockholm. Rätt att delta och anmälan Aktieägare som önskar att deltaga i årsstämman ska dels vara registrerad i eget namn i den av Euroclear Sweden AB förda aktieboken för Bolaget senast onsdagen den 21 juni 2023,dels anmäla sitt deltagande till Bolaget senast fredagen den 23 juni 2023. Anmälan om deltagande i årsstämman ska ske per telefon till +44 (0)758 4301260 eller via e-post till AGM@anoto.com. Vid anmälan ska namn, personnummer/organisationsnummer samt registrerat aktieinnehav uppges. Fullmakter, registreringsbevis och andra behörighetshandlingar bör för att underlätta inpasseringen vid stämman skickas till Bolaget via e-post till AGM@anoto.com senast fredagen den 23 juni 2023. Bolaget tillhandahåller fullmaktsformulär på Bolagets hemsida www.anoto.com. För att ha rätt att delta i stämman måste
Aegon completes sale of Central and Eastern European Businesses to VIG1.6.2023 08:00:00 CEST | Press release
The Hague, June 1, 2023 - Aegon today announces the completion of the divestment of its businesses in Poland and Romania to Vienna Insurance Group AG Wiener Versicherung Gruppe (VIG) for EUR 125 million. This was the final step to complete the full sale of Aegon’s insurance, pension and asset management business in Central and Eastern Europe to VIG, following the closings of the divestments of the Hungarian and Turkish businesses. “We are very pleased that we have now finalized the full divestment of our Central and Eastern European businesses. As part of Aegon’s transformation and sharpened focus, the closing allows us to fully concentrate on the countries and business lines where we can add most value, while our former businesses will start their new chapter as part of VIG,” says Lard Friese, CEO of Aegon. “I would like to sincerely thank our employees in Hungary, Poland, Romania and Turkey for their important contributions to Aegon over the years and I wish them all the best in thei
Notice to attend the Annual General Meeting in Anoto Group AB (publ)1.6.2023 08:00:00 CEST | Press release
The shareholders of Anoto Group AB (publ) (the “Company”) are hereby invited to attend the Annual General Meeting (the “AGM”) to be held on Friday30 June 2023 at 10 a.m. at the premises of SetterwallsAdvokatbyrå, Sturegatan 10 in Stockholm, Sweden. Notification of participation Shareholders wishing to attend the AGM must be entered as shareholders in the share register maintained by Euroclear Sweden AB no later than on Wednesday 21 June 2023,notify the Company of their intention to participate no later than on Friday 23 June 2023. Attendance is to be notified by phone to +44 (0)758 430 12 60 or by e-mail to AGM@anoto.com. The notification should state name, social security number/corporate identification number and registered number of shares. To facilitate admittance to the AGM, proxies, registration certificates and other authorisation documents should be submitted to the Company by email to AGM@anoto.com no later than on Friday 23 June 2023. The Company provides proxy forms on the C
Van Lanschot Kempen successfully issued €500 million Soft Bullet Covered Bond1.6.2023 08:00:00 CEST | Press release
Amsterdam/’s-Hertogenbosch, the Netherlands, 1 June 2023 31 May 2023, Van Lanschot Kempen successfully issued a €500 million 3 year Soft Bullet Covered Bond with a 3.5% fixed coupon. The deal had a final order book of €2 billion and was placed with a broad range of European institutional investors. The transaction further strengthens and diversifies Van Lanschot Kempen’s funding profile. The bonds are rated AAA by Standard & Poor’s. Van Lanschot Kempen’s Soft Bullet Covered Bond Programme is Dutch law-based and backed by a pool of Dutch residential mortgage loans. It is registered with De Nederlandsche Bank and is both UCITS-compliant and CRD-compliant. Van Lanschot Kempen mandated BNP Paribas, DZ Bank, ING, LBBW and Rabobank as Joint Lead Managers for this transaction. Media Relations: +31 20 354 45 85; email@example.com Investor Relations: +31 20 354 45 90; firstname.lastname@example.org About Van Lanschot Kempen Van Lanschot Kempen is an independent, spec
PGS - Mediterranean Contract Award1.6.2023 08:00:00 CEST | Press release
June 1, 2023, Oslo, Norway: PGS is awarded a 3D exploration acquisition contract in the Mediterranean by a major international energy company. Ramform Hyperion is expected to mobilize for the survey late third quarter and the program has a total duration of approximately 70 days. “We are very pleased with this contract award, which improves our visibility into the fourth quarter. There is increasing exploration interest in the Mediterranean following recent discoveries in this prolific gas province, and this award builds on our successful campaign from the previous season,” says President & CEO in PGS, Rune Olav Pedersen. PGS announces contract awards and MultiClient projects as stock exchange releases if the contract has a value of $10 million or more, MultiClient projects with a duration of 2 months or more and strategically important contracts. FOR DETAILS, CONTACT:Bård Stenberg, VP IR & Corporate Communication Mobile: +47 992 45 235 *** PGS ASA and its subsidiaries (“PGS” or “the C